
Shares of Israel-based drug developer SciSparc SPRC.O rise 13.5% to $2.76
Co says it has agreed to buy portfolio of patents and intellectual property for medical devices from Xylo Technologies
Deal includes "MUSE system," a single-use endoscopic device used in minimally invasive procedure to treat acid reflux disease, known as GERD
Xylo to get 19.99% of SPRC's share capital or pre-funded warrants at closing, co says
Co says it plans to replicate Xylo's China commercialization model in North America, Europe and Latin America
Including session's move, stock down ~63% YTD